Pharmacology - 13:01
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Art - Nov 13
Midlands Art Papers launches special issue on inclusion, disability and access in the arts
Midlands Art Papers launches special issue on inclusion, disability and access in the arts
Pharmacology - Nov 12
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
Health - Nov 12
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Life Sciences - Nov 12
Stanford opens ’team science’ complex for brain research and molecular discovery
Stanford opens ’team science’ complex for brain research and molecular discovery
science wire
« BACK
Pharmacology - 05.09.2019
Pharmacology - 04.09.2019
Pharmacology - Health - 04.09.2019
Pharmacology - Health - 03.09.2019
Health - Pharmacology - 03.09.2019
Pharmacology - Health - 02.09.2019
Health - Pharmacology - 02.09.2019
Pharmacology - Health - 02.09.2019
Pharmacology - Health - 01.09.2019
Pharmacology - Health - 01.09.2019
Pharmacology - Health - 30.08.2019
Pharmacology - Physics - 29.08.2019 
A biosensor to help rheumatoid arthritis patients
This Friday, 30 August, a team of EPFL students will take part in the SensUs competition at the Eindhoven University of Technology.
Health - Pharmacology - 29.08.2019
Pharmacology - Health - 29.08.2019
Pharmacology - Health - 29.08.2019
Pharmacology - 28.08.2019
Pharmacology - Health - 28.08.2019 
New patient test could tell GPs if infections are antibiotic resistant in under two hours
A new rapid patient test which could identify whether bacteria isolated from clinical samples are antibiotic resistant in under two hours is being trialled on a range of antibiotics commonly used to treat urinary tract infections (UTIs).
Pharmacology - Health - 21.08.2019
Pharmacology - Health - 19.08.2019
Life Sciences - Pharmacology - 16.08.2019
Pharmacology - Health - 16.08.2019
Pharmacology - Health - 09.08.2019
Health - Pharmacology - 07.08.2019 
Tiny biodegradable circuits for releasing painkillers inside the body
EPFL researchers have developed biodegradable microresonators that can be heated locally with a wireless system.
Pharmacology - Life Sciences - 07.08.2019
Pharmacology - Health - 05.08.2019
Career - Pharmacology - 05.08.2019
Pharmacology - Health - 31.07.2019
Pharmacology - Health - 30.07.2019
Health - Pharmacology - 26.07.2019
Pharmacology - Health - 26.07.2019
Pharmacology - Health - 26.07.2019
Pharmacology - 23.07.2019
Health - Pharmacology - 22.07.2019
Pharmacology - Health - 19.07.2019
Pharmacology - Business / Economics - 18.07.2019
Health - Pharmacology - 16.07.2019
Health - Pharmacology - 15.07.2019
Pharmacology - Health - 11.07.2019
Pharmacology - 11.07.2019
Pharmacology - Health - 09.07.2019
Health - Pharmacology - 02.07.2019
Pharmacology - Health - 02.07.2019
Pharmacology - Health - 01.07.2019
Pharmacology - Health - 01.07.2019
Pharmacology - Health - 01.07.2019
Health - Pharmacology - 28.06.2019
Pharmacology - Administration - 28.06.2019
Health - Pharmacology - 28.06.2019 
Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment. Breast cancer survivor Joy Jensen said such a test would give control back to those who felt helpless about their situation.
Pharmacology - Health - 26.06.2019
Health - Pharmacology - 24.06.2019
Pharmacology
Results 101 - 150 of 1505.
Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neurofilament light chain levels as a potential biomarker for predicting MS disability progression; new longer-term OCREVUS (ocrelizumab) data of more than six years show reduction of disability progression in relapsing and primary progressive MS Breadth
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neurofilament light chain levels as a potential biomarker for predicting MS disability progression; new longer-term OCREVUS (ocrelizumab) data of more than six years show reduction of disability progression in relapsing and primary progressive MS Breadth
Poor diet can lead to blindness
An extreme case of "fussy" or "picky" eating caused a young patient's blindness, according to a new case report published today [2 Sep 2019] in Annals of Internal Medicine.
An extreme case of "fussy" or "picky" eating caused a young patient's blindness, according to a new case report published today [2 Sep 2019] in Annals of Internal Medicine.
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients ; EVALUATE-HF results complement findings PROVE-HF establishes significant correlation between improvement in widely used cardiac biomarker and positive changes in heart structure and ability to pump blood in patients taking Entresto Safety and tole
Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients ; EVALUATE-HF results complement findings PROVE-HF establishes significant correlation between improvement in widely used cardiac biomarker and positive changes in heart structure and ability to pump blood in patients taking Entresto Safety and tole
Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%
BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an
BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an
Roche presents positive phase III study results for one-dose Xofluza in children with flu
Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose
Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose
Novartis PARAGON-HF trial suggests Entresto benefit in HFpEF patients but narrowly misses primary endpoint
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.059) Totality of evidence, including improvement in various measures of symptoms, quality of life, and renal function, suggests clinically important benefits in HFpEF Entresto was well tolerated and the overall safety profile was comparable
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.059) Totality of evidence, including improvement in various measures of symptoms, quality of life, and renal function, suggests clinically important benefits in HFpEF Entresto was well tolerated and the overall safety profile was comparable
Preserved Heart Failure Trial Misses Endpoint, But Drug May Benefit Some Patients
The number of patients with heart failure with preserved ejection fraction is on the rise, and the search is on for a therapy that can improve health outcomes in this group of patients for whom no approved therapies are available.
The number of patients with heart failure with preserved ejection fraction is on the rise, and the search is on for a therapy that can improve health outcomes in this group of patients for whom no approved therapies are available.
Novartis ofatumumab demonstrates superiority versus Aubagio in two head-to-head Phase III multiple sclerosis studies
In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio * (teriflunomide) in patients with relapsing forms of MS (RMS) Key secondary endpoi
In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio * (teriflunomide) in patients with relapsing forms of MS (RMS) Key secondary endpoi
This Friday, 30 August, a team of EPFL students will take part in the SensUs competition at the Eindhoven University of Technology.
European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer - an aggressive and difficult-to-treat disease Approval based on the
The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer - an aggressive and difficult-to-treat disease Approval based on the
Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq
This launch represents an important step in Roche's personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine Each year 300,000 patients around the
This launch represents an important step in Roche's personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine Each year 300,000 patients around the
A new rapid patient test which could identify whether bacteria isolated from clinical samples are antibiotic resistant in under two hours is being trialled on a range of antibiotics commonly used to treat urinary tract infections (UTIs).
Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019
PARAGON-HF trial will provide Entresto (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF) New PROVE-HF and EVALUATE-HF studies will highlight Entresto's direct impact on the heart in heart failure with reduced ejection fraction (HFrEF) New PIONEER-HF and TRANSITION-HF findings will advance understanding of Entresto use in patients hospitalized for decompensated HFrEF following stabilizatio
PARAGON-HF trial will provide Entresto (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF) New PROVE-HF and EVALUATE-HF studies will highlight Entresto's direct impact on the heart in heart failure with reduced ejection fraction (HFrEF) New PIONEER-HF and TRANSITION-HF findings will advance understanding of Entresto use in patients hospitalized for decompensated HFrEF following stabilizatio
Berkeley Talks transcript: Take an intoxicating plants tour at UC Botanical Garden
Sal Levinson: I'm Sal Levinson - I'm a propagator at the UC Botanical Garden. I work in native propagation, I grow plants that we sell here, and I also do the butterfly tours here.
Sal Levinson: I'm Sal Levinson - I'm a propagator at the UC Botanical Garden. I work in native propagation, I grow plants that we sell here, and I also do the butterfly tours here.
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?
EPFL researchers have developed biodegradable microresonators that can be heated locally with a wireless system.
Novartis stands behind Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
Basel, August 6, 2019 - Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma. The FDA supports the continued marketing and use of Zolgensma for patients with spinal muscular atrophy (SMA) less than 2 years of age.
Basel, August 6, 2019 - Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma. The FDA supports the continued marketing and use of Zolgensma for patients with spinal muscular atrophy (SMA) less than 2 years of age.
Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc
Roche and Spark Therapeutics, Inc.
Roche and Spark Therapeutics, Inc.
Yale and Mayo Clinic awarded FDA grant to study opioid prescribing and use
Yale University and Mayo Clinic have been awarded a grant for up to $5.3 million over two years by the U.S. Food and Drug Administration (FDA) to study patients' experiences with pain and use of opioids prescribed for acute pain. This project is part of the Center of Excellence in Regulatory Science and Innovation (CERSI) , a joint effort between Yale, Mayo Clinic, and the FDA.
Yale University and Mayo Clinic have been awarded a grant for up to $5.3 million over two years by the U.S. Food and Drug Administration (FDA) to study patients' experiences with pain and use of opioids prescribed for acute pain. This project is part of the Center of Excellence in Regulatory Science and Innovation (CERSI) , a joint effort between Yale, Mayo Clinic, and the FDA.
Superbugs: A Pop-Up Science Shop (29th July - 11th August)
Ever wondered what micro-organisms are living on your skin? Drop into our interactive lab in the heart of Cardiff's busy shopping centre to find out, and you can even get pictures of them! Cardiff Un
Ever wondered what micro-organisms are living on your skin? Drop into our interactive lab in the heart of Cardiff's busy shopping centre to find out, and you can even get pictures of them! Cardiff Un
Novartis receives positive CHMP opinion for Lucentis treatment
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Pha
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Pha
CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy
Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years
Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from stand
FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from stand
Pioneering children’s cancer research role to speed up crucial clinical trials
University of Birmingham researchers are leading the way with a ground-breaking role to enable more children with the rare cancer neuroblastoma to access potentially life-saving clinical trials more quickly.
University of Birmingham researchers are leading the way with a ground-breaking role to enable more children with the rare cancer neuroblastoma to access potentially life-saving clinical trials more quickly.
Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of
New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of
CHMP recommends EU approval of Tecentriq for people with breast cancer
Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive Phase III cancer immunother
Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive Phase III cancer immunother
Sussex Drug Discovery Centre appoints Professor Jeffrey Hill as new Director
Professor Jeffrey Hill has been appointed as the new Director of the Sussex Drug Discovery Centre ( SDDC ) within the School of Life Sciences.
Professor Jeffrey Hill has been appointed as the new Director of the Sussex Drug Discovery Centre ( SDDC ) within the School of Life Sciences.
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment. Breast cancer survivor Joy Jensen said such a test would give control back to those who felt helpless about their situation.
Long delays prescribing new antibiotics hinder market for needed drugs
U.S. hospitals wait over a year on average to begin prescribing newly developed antibiotics, a delay that might threaten the supply or discourage future development of needed drugs.
U.S. hospitals wait over a year on average to begin prescribing newly developed antibiotics, a delay that might threaten the supply or discourage future development of needed drugs.
Pharmacology - 13:01
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Art - Nov 13
Midlands Art Papers launches special issue on inclusion, disability and access in the arts
Midlands Art Papers launches special issue on inclusion, disability and access in the arts
Pharmacology - Nov 12
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
Health - Nov 12
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Life Sciences - Nov 12
Stanford opens ’team science’ complex for brain research and molecular discovery
Stanford opens ’team science’ complex for brain research and molecular discovery